microRNA-210 (miR-210) is the master hypoxia-inducible miRNA (hypoxamiR) since it has been found to be significantly upregulated under hypoxia in a wide range of cell types.
Recent advances:
Gene ontology analysis of its targets indicates that miR-210 modulates several aspects of cellular response to hypoxia. Due to its high pleiotropy, miR-210 not only plays a protective role by fine-tuning mitochondrial metabolism and inhibiting red-ox imbalance and apoptosis, but it can also promote cell proliferation, differentiation, and migration, substantially contributing to angiogenesis.
Critical issues:
As most miRNAs, modulating different gene pathways, also miR-210 can potentially lead to different and even opposite effects, depending on the physio-pathological contexts in which it acts.
Future direction:
The use of miRNAs as therapeutics is a fast growing field. This review aimed at highlighting the role of miR-210 in angiogenesis in the context of ischemic cardiovascular diseases and diabetes in order to clarify the molecular mechanisms underpinning miR-210 action. Particular attention will be dedicated to experimentally validated miR-210 direct targets involved in cellular processes related to angiogenesis and diabetes mellitus, such as mitochondrial metabolism, redox balance, apoptosis, migration, and adhesion. Antioxid. Redox Signal. 36, 685–706.
Get full access to this article
View all access options for this article.
References
1.
AdamsJA, UryashA, LopezJR, and SacknerMA. The endothelium as a therapeutic target in diabetes: a narrative review and perspective. Front Physiol, 12: 638491, 2021.
2.
AgarwalV, BellGW, NamJW, and BartelDP. Predicting effective microRNA target sites in mammalian mRNAs. Elife, 4: e05005, 2015.
3.
AlaitiMA, IshikawaM, MasudaH, SimonDI, JainMK, AsaharaT, and CostaMA. Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med, 16: 2413–2421, 2012.
4.
AmbrosV.The functions of animal microRNAs. Nature, 431: 350–355, 2004.
5.
AmrKS, AbdelmawgoudH, AliZY, ShehataS, and RaslanHM. Potential value of circulating microRNA-126 and microRNA-210 as biomarkers for type 2 diabetes with coronary artery disease. Br J Biomed Sci, 75: 82–87, 2018.
6.
ArdenGB and SivaprasadS. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev, 7: 291–304, 2011.
7.
ArifM, PandeyR, AlamP, JiangS, SadayappanS, PaulA, and AhmedRPH. MicroRNA-210-mediated proliferation, survival, and angiogenesis promote cardiac repair post myocardial infarction in rodents. J Mol Med (Berl), 95: 1369–1385, 2017.
8.
AssmannTS, Recamonde-MendozaM, PuñalesM, TschiedelB, CananiLH, and CrispimD. MicroRNA expression profile in plasma from type 1 diabetic patients: case-control study and bioinformatic analysis. Diabetes Res Clin Pract, 141: 35–46, 2018.
9.
AvitabileC, AccardoA, RinghieriP, MorelliG, SavianoM, MontagnerG, FabbriE, GalleraniE, GambariR, and RomanelliA. Incorporation of naked peptide nucleic acids into liposomes leads to fast and efficient delivery. Bioconjug Chem, 26: 1533–1541, 2015.
10.
BalsaE, MarcoR, Perales-ClementeE, SzklarczykR, CalvoE, LandázuriMO, and EnríquezJA. NDUFA4 is a subunit of complex IV of the mammalian electron transport chain. Cell Metab, 16: 378–386, 2012.
11.
BaoQ, Jia HA R, CaoZ, and ZhangY. MiR-210 inhibits hypoxia-induced apoptosis of smooth muscle cells via targeting MEF2C. Int J Clin Exp Pathol, 12: 1846–1858, 2019.
BerteroT, RezzonicoR, PottierN, and MariB. Impact of MicroRNAs in the Cellular Response to Hypoxia. Int Rev Cell Mol Biol, 333: 91–158, 2017.
14.
BesnierM, GasparinoS, VonoR, SangalliE, FacoettiA, BollatiV, CantoneL, ZaccagniniG, MaimoneB, FuschiP, Da SilvaD, SchiavulliM, AdayS, CaputoM, MadedduP, EmanueliC, MartelliF, and SpinettiG. miR-210 enhances the therapeutic potential of bone-marrow-derived circulating proangiogenic cells in the setting of limb ischemia. Mol Ther, 26: 1694–1705, 2018.
15.
BianWS, ShiPX, MiXF, SunYY, YangDD, GaoBF, WuSX, and FanGC. MiR-210 protects cardiomyocytes from OGD/R injury by inhibiting E2F3. Eur Rev Med Pharmacol Sci, 22: 743–749, 2018.
16.
BiswasS, RoyS, BanerjeeJ, HussainSR, KhannaS, MeenakshisundaramG, KuppusamyP, FriedmanA, and SenCK. Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci U S A, 107: 6976–6981, 2010.
17.
BostjancicE, ZidarN, and GlavacD. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers, 27: 255–268, 2009.
18.
BotusanIR, SunkariVG, SavuO, CatrinaAI, GrünlerJ, LindbergS, PereiraT, Ylä-HerttualaS, PoellingerL, BrismarK, and CatrinaSB. Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci U S A, 105: 19426–19431, 2008.
19.
CampsC, BuffaFM, ColellaS, MooreJ, SotiriouC, SheldonH, HarrisAL, GleadleJM, and RagoussisJ. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res, 14: 1340–1348, 2008.
20.
CatrinaSB and ZhengX. Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia, 64: 709–716, 2021.
21.
ChanSY and LoscalzoJ. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle, 9: 1072–1083, 2010.
22.
ChanSY, ZhangYY, HemannC, MahoneyCE, ZweierJL, and LoscalzoJ. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab, 10: 273–284, 2009.
23.
ChanYC, BanerjeeJ, ChoiSY, and SenCK. miR-210: the master hypoxamir. Microcirculation, 19: 215–223, 2012.
24.
ChenKC, LiaoYC, WangJY, LinYC, ChenCH, and JuoSH. Oxidized low-density lipoprotein is a common risk factor for cardiovascular diseases and gastroenterological cancers via epigenomical regulation of microRNA-210. Oncotarget, 6: 24105–24118, 2015.
25.
ChenWY, LiuWJ, ZhaoYP, ZhouL, ZhangTP, ChenG, and ShuH. Induction, modulation and potential targets of miR-210 in pancreatic cancer cells. Hepatobiliary Pancreat Dis Int, 11: 319–324, 2012.
26.
ChenZ, LiY, ZhangH, HuangP, and LuthraR. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene, 29: 4362–4368, 2010.
27.
ChengH, ChangS, XuR, ChenL, SongX, WuJ, QianJ, ZouY, and MaJ. Hypoxia-challenged MSC-derived exosomes deliver miR-210 to attenuate post-infarction cardiac apoptosis. Stem Cell Res Ther 11: 224-020-0173, 7-0, 2020.
ChoNH, ShawJE, KarurangaS, HuangY, da Rocha FernandesJD, OhlroggeAW, and MalandaB. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract, 138: 271–281, 2018.
30.
CicchillittiL, Di StefanoV, IsaiaE, CrimaldiL, FasanaroP, AmbrosinoV, AntoniniA, CapogrossiMC, GaetanoC, PiaggioG, and MartelliF. Hypoxia-inducible factor 1-α induces miR-210 in normoxic differentiating myoblasts. J Biol Chem, 287: 44761–44771, 2012.
31.
CostalesMG, HagaCL, VelagapudiSP, Childs-DisneyJL, PhinneyDG, and DisneyMD. Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit. J Am Chem Soc, 139: 3446–3455, 2017.
32.
CostalesMG, SureshB, VishnuK, and DisneyMD. Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA. Cell Chem Biol, 26: 1180–1186.e5, 2019.
33.
CostantinoS, PaneniF, LüscherTF, and CosentinoF. MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. Eur Heart J, 37: 572–576, 2016.
34.
CrosbyME, KulshreshthaR, IvanM, and GlazerPM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res, 69: 1221–1229, 2009.
35.
DallasA, TrotsyukA, IlvesH, BonhamCA, RodriguesM, EngelK, BarreraJA, KosaricN, Stern-BuchbinderZA, WhiteA, MandellKJ, HammondPT, MansbridgeJ, JayasenaS, GurtnerGC, and JohnstonBH. Acceleration of diabetic wound healing with PHD2- and miR-210-targeting oligonucleotides. Tissue Eng Part A, 25: 44–54, 2019.
36.
DevlinC, GrecoS, MartelliF, and IvanM. miR-210: more than a silent player in hypoxia. IUBMB Life, 63: 94–100, 2011.
EkimlerS and SahinK. Computational Methods for MicroRNA Target Prediction. Genes (Basel), 5: 671–683, 2014.
41.
FabbriE, ManicardiA, TedeschiT, SforzaS, BianchiN, BrognaraE, FinottiA, BreveglieriG, BorgattiM, CorradiniR, MarchelliR, and GambariR. Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). ChemMedChem, 6: 2192–2202, 2011.
42.
FanZG, QuXL, ChuP, GaoYL, GaoXF, ChenSL, and TianNL. MicroRNA-210 promotes angiogenesis in acute myocardial infarction. Mol Med Rep, 17: 5658–5665, 2018.
43.
FasanaroP, D'AlessandraY, Di StefanoV, MelchionnaR, RomaniS, PompilioG, CapogrossiMC, and MartelliF. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem, 283: 15878–15883, 2008.
44.
FasanaroP, GrecoS, LorenziM, PescatoriM, BrioschiM, KulshreshthaR, BanfiC, StubbsA, CalinGA, IvanM, CapogrossiMC, and MartelliF. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem, 284: 35134–35143, 2009.
45.
FasanaroP, RomaniS, VoellenkleC, MaimoneB, CapogrossiMC, and MartelliF. ROD1 is a seedless target gene of hypoxia-induced miR-210. PLoS One, 7: e44651, 2012.
46.
FavaroE, RamachandranA, McCormickR, GeeH, BlancherC, CrosbyM, DevlinC, BlickC, BuffaF, LiJL, VojnovicB, Pires das NevesR, GlazerP, IborraF, IvanM, RagoussisJ, and HarrisAL. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One, 5: e10345, 2010.
47.
FerkoM, AndelováN, Szeiffová BačováB, and JašováM. Myocardial adaptation in pseudohypoxia: signaling and regulation of mPTP via Mitochondrial Connexin 43 and Cardiolipin. Cells, 8: 1449, 2019.
48.
FujitaY, ArayaJ, ItoS, KobayashiK, KosakaN, YoshiokaY, KadotaT, HaraH, KuwanoK, and OchiyaT. Suppression of autophagy by extracellular vesicles promotes myofibroblast differentiation in COPD pathogenesis. J Extracell Vesicles, 4: 28388, 2015.
49.
GangadaranP, RajendranRL, OhJM, HongCM, JeongSY, LeeSW, LeeJ, and AhnBC. Extracellular vesicles derived from macrophage promote angiogenesis In vitro and accelerate new vasculature formation In vivo. Exp Cell Res, 394: 112146, 2020.
GiannakakisA, SandaltzopoulosR, GreshockJ, LiangS, HuangJ, HasegawaK, LiC, O'Brien-JenkinsA, KatsarosD, WeberBL, SimonC, CoukosG, and ZhangL. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther, 7: 255–264, 2008.
52.
Gollmann-TepeköylüC, LobenweinD, TheurlM, PrimessnigU, LenerD, KirchmairE, MathesW, GraberM, PölzlL, AnA, KozielK, PechrigglE, VoelklJ, PaulusP, SchadenW, GrimmM, KirchmairR, and HolfeldJ. Shock Wave Therapy Improves Cardiac Function in a Model of Chronic Ischemic Heart Failure: Evidence for a Mechanism Involving VEGF Signaling and the Extracellular Matrix. J Am Heart Assoc, 7: e010025, 2018.
53.
GouD, RamchandranR, PengX, YaoL, KangK, SarkarJ, WangZ, ZhouG, and RajJU. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol, 303: L682–L691, 2012.
54.
GrecoS, FasanaroP, CastelvecchioS, D'AlessandraY, ArcelliD, Di DonatoM, MalavazosA, CapogrossiMC, MenicantiL, and MartelliF. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes, 61: 1633–1641, 2012.
55.
GrecoS, GaetanoC, and MartelliF. HypoxamiR regulation and function in ischemic cardiovascular diseases. Antioxid Redox Signal, 21: 1202–1219, 2014.
56.
GrossoS, DoyenJ, ParksSK, BerteroT, PayeA, CardinaudB, GounonP, Lacas-GervaisS, NoëlA, PouysségurJ, BarbryP, MazureNM, and MariB. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis, 4: e544, 2013.
57.
GuHF, ZhengX, Abu SemanN, GuT, BotusanIR, SunkariVG, LokmanEF, BrismarK, and CatrinaSB. Impact of the hypoxia-inducible factor-1 α (HIF1A) Pro582Ser polymorphism on diabetes nephropathy. Diabetes Care, 36: 415–421, 2013.
58.
GuanY, SongX, SunW, WangY, and LiuB. Effect of Hypoxia-Induced MicroRNA-210 Expression on Cardiovascular Disease and the Underlying Mechanism. Oxid Med Cell Longev, 2019: 4727283, 2019.
59.
GuptaA, QuijanoE, LiuY, BahalR, ScanlonSE, SongE, HsiehWC, BraddockDE, LyDH, SaltzmanWM, and GlazerPM. Anti-tumor Activity of miniPEG-γ-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy. Mol Ther Nucleic Acids, 9: 111–119, 2017.
60.
HafnerM, LianoglouS, TuschlT, and BetelD. Genome-wide identification of miRNA targets by PAR-CLIP. Methods, 58: 94–105, 2012.
61.
HaiderHK and AshrafM. Preconditioning and stem cell survival. J Cardiovasc Transl Res, 3: 89–102, 2010.
62.
HaleA, LeeC, AnnisS, MinPK, PandeR, CreagerMA, JulianCG, MooreLG, MitsialisSA, HwangSJ, KourembanasS, and ChanSY. An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells. Biochim Biophys Acta, 1843: 2528–2542, 2014.
63.
HayashiY, YokotaA, HaradaH, and HuangG. Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1α in cancer. Cancer Sci, 110: 1510–1517, 2019.
64.
HeJ, WuJ, XuN, XieW, LiM, LiJ, JiangY, YangBB, and ZhangY. MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res, 41: 498–508, 2013.
65.
HeuschG.Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol, 17: 773–789, 2020.
66.
HuS, HuangM, LiZ, JiaF, GhoshZ, LijkwanMA, FasanaroP, SunN, WangX, MartelliF, RobbinsRC, and WuJC. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation, 122: S124–S131, 2010.
67.
HuXQ, DasguptaC, XiaoD, HuangX, YangS, and ZhangL. MicroRNA-210 Targets Ten-Eleven Translocation Methylcytosine Dioxygenase 1 and Suppresses Pregnancy-Mediated Adaptation of Large Conductance Ca(2+)-Activated K(+) Channel Expression and Function in Ovine Uterine Arteries. Hypertension, 2017. [Epub ahead of print] DOI: 10.1161/HYPERTENSIONAHA.117.09864.
68.
HuangL, MaQ, LiY, LiB, and ZhangL. Inhibition of microRNA-210 suppresses pro-inflammatory response and reduces acute brain injury of ischemic stroke in mice. Exp Neurol, 300: 41–50, 2018.
IvanM and HuangX. miR-210: fine-tuning the hypoxic response. Adv Exp Med Biol, 772: 205–227, 2014.
71.
IvanM and KaelinWGJr. The EGLN-HIF O(2)-Sensing System: Multiple Inputs and Feedbacks. Mol Cell, 66: 772–779, 2017.
72.
JeyaseelanK, LimKY, and ArmugamA. MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke, 39: 959–966, 2008.
73.
JiangY, LiL, TanX, LiuB, ZhangY, and LiC. miR-210 mediates vagus nerve stimulation-induced antioxidant stress and anti-apoptosis reactions following cerebral ischemia/reperfusion injury in rats. J Neurochem, 134: 173–181, 2015.
74.
JinY, WeiJ, XuS, GuanF, YinL, and ZhuH. miR-210-3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3. Mol Med Rep, 19: 4946–4954, 2019.
75.
JuS, LiangZ, LiC, DingC, XuC, SongX, and ZhaoJ. The effect and mechanism of miR-210 in down-regulating the autophagy of lung cancer cells. Pathol Res Pract, 215: 453–458, 2019.
76.
KaneNM, MeloniM, SpencerHL, CraigMA, StrehlR, MilliganG, HouslayMD, MountfordJC, EmanueliC, and BakerAH. Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol, 30: 1389–1397, 2010.
77.
KellyTJ, SouzaAL, ClishCB, and PuigserverP. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol, 31: 2696–2706, 2011.
78.
KidoM, DuL, SullivanCC, LiX, DeutschR, JamiesonSW, and ThistlethwaitePA. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol, 46: 2116–2124, 2005.
79.
KigaK, MimuroH, SuzukiM, Shinozaki-UshikuA, KobayashiT, SanadaT, KimM, OgawaM, IwasakiYW, KayoH, Fukuda-YuzawaY, YashiroM, FukayamaM, FukaoT, and SasakawaC. Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. Nat Commun, 5: 4497, 2014.
80.
KimHW, HaiderHK, JiangS, and AshrafM. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem, 284: 33161–33168, 2009.
81.
KimHW, JiangS, AshrafM, and HaiderKH. Stem cell-based delivery of Hypoxamir-210 to the infarcted heart: implications on stem cell survival and preservation of infarcted heart function. J Mol Med (Berl), 90: 997–1010, 2012.
82.
KimJH, ParkSG, SongSY, KimJK, and SungJH. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis, 4: e588, 2013.
83.
KulshreshthaR, FerracinM, WojcikSE, GarzonR, AlderH, Agosto-PerezFJ, DavuluriR, LiuCG, CroceCM, NegriniM, CalinGA, and IvanM. A microRNA signature of hypoxia. Mol Cell Biol, 27: 1859–1867, 2007.
84.
LaiCH, BarikP, HsiehDJ, DayCH, HoTJ, ChenRJ, KuoWW, PadmaVV, ShibuMA, and HuangCY. Inhibition of cell death-inducing p53 target 1 through miR-210-3p overexpression attenuates reactive oxygen species and apoptosis in rat adipose-derived stem cells challenged with Angiotensin II. Biochem Biophys Res Commun, 532: 347–354, 2020.
85.
LanahanAA, LechD, DubracA, ZhangJ, ZhuangZW, EichmannA, and SimonsM. PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation, 130: 902–909, 2014.
86.
LeeDW, FutamiM, CarrollM, FengY, WangZ, FernandezM, WhichardZ, ChenY, KornblauS, ShpallEJ, Bueso-RamosCE, and CoreySJ. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene, 31: 4085–4094, 2012.
87.
LeeY and GustafssonAB. Role of apoptosis in cardiovascular disease. Apoptosis, 14: 536–548, 2009.
LeyK, MillerYI, and HedrickCC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol, 31: 1506–1516, 2011.
90.
LiL, HuangX, HeZ, XiongY, and FangQ. miRNA-210-3p regulates trophoblast proliferation and invasiveness through fibroblast growth factor 1 in selective intrauterine growth restriction. J Cell Mol Med, 23: 4422–4433, 2019.
91.
LiS, YangJ, WangJ, GaoW, DingY, DingY, and JiaZ. Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1. Cell Biosci, 8: 9-018-0209-3. eCollection 2018, 2018.
92.
LiT, SongX, ZhangJ, ZhaoL, ShiY, LiZ, LiuJ, LiuN, YanY, XiaoY, TianX, SunW, GuanY, and LiuB. Protection of human umbilical vein endothelial cells against oxidative stress by MicroRNA-210. Oxid Med Cell Longev, 2017: 3565613, 2017.
93.
LiX, JiaZ, ZhaoX, XuM, and ChenM. Expression of miR-210 in the peripheral blood of patients with newly diagnosed type 2 diabetes mellitus and its effect on the number and function of endothelial progenitor cells. Microvasc Res, 131: 104032, 2020.
94.
LiY, YangC, ZhangL, and YangP. MicroRNA-210 induces endothelial cell apoptosis by directly targeting PDK1 in the setting of atherosclerosis. Cell Mol Biol Lett, 22: 3-017-0033-5. eCollection 2017, 2017.
95.
LiangWC, WangY, WanDC, YeungVS, and WayeMM. Characterization of miR-210 in 3T3-L1 adipogenesis. J Cell Biochem, 114: 2699–2707, 2013.
96.
LiuD, XiaH, WangF, ChenC, and LongJ. MicroRNA-210 interacts with FBXO31 to regulate cancer proliferation cell cycle and migration in human breast cancer. Onco Targets Ther, 9: 5245–5255, 2016.
97.
LiuF, LouYL, WuJ, RuanQF, XieA, GuoF, CuiSP, DengZF, and WangY. Upregulation of microRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro. Kidney Blood Press Res, 35: 182–191, 2012.
98.
LiuH, WangJ, ChenY, ChenY, MaX, BihlJC, and YangY. NPC-EXs Alleviate Endothelial Oxidative Stress and Dysfunction through the miR-210 Downstream Nox2 and VEGFR2 Pathways. Oxid Med Cell Longev, 2017: 9397631, 2017.
99.
LiuM, LiuH, and DudleySCJr. Reactive oxygen species originating from mitochondria regulate the cardiac sodium channel. Circ Res, 107: 967–974, 2010.
100.
LiuW, JiangD, GongF, HuangY, LuoY, RongY, WangJ, GeX, JiC, FanJ, and CaiW. miR-210-5p promotes epithelial-mesenchymal transition by inhibiting PIK3R5 thereby activating oncogenic autophagy in osteosarcoma cells. Cell Death Dis 11: 93-020-227, 0-1, 2020.
101.
LiuX, ZhangC, WangC, SunJ, WangD, ZhaoY, and XuX. miR-210 promotes human osteosarcoma cell migration and invasion by targeting FGFRL1. Oncol Lett, 16: 2229–2236, 2018.
102.
LiuY, HanY, ZhangH, NieL, JiangZ, FaP, GuiY, and CaiZ. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One, 7: e52280, 2012.
103.
LouY, GaoF, XieA, GuoF, DengZ, and WangY. MicroRNA-210 modified human umbilical vein endothelial cells induce capillary formation. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 26: 587–591, 2012.
104.
LouYL, GuoF, LiuF, GaoFL, ZhangPQ, NiuX, GuoSC, YinJH, WangY, and DengZF. miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. Mol Cell Biochem, 370: 45–51, 2012.
105.
LuWJ, LiangHB, LiYF, TuXQ, HeJR, DingKQ, YangGY, XinXY, and ZengLL. MicroRNA-210-3p Targets RGMA to enhance the angiogenic functions of endothelial progenitor cells under hypoxic conditions. Front Cell Neurosci, 13: 223, 2019.
106.
LukasikA and ZielenkiewiczP. An Overview of miRNA and miRNA target analysis tools. Methods Mol Biol, 1932: 65–87, 2019.
107.
LuoR, WangY, XuP, CaoG, ZhaoY, ShaoX, LiYX, ChangC, PengC, and WangYL. Hypoxia-inducible miR-210 contributes to preeclampsia via targeting thrombospondin type I domain containing 7A. Sci Rep, 6: 19588, 2016.
108.
MaQ, DasguptaC, ShenG, LiY, and ZhangL. MicroRNA-210 downregulates TET2 and contributes to inflammatory response in neonatal hypoxic-ischemic brain injury. J Neuroinflammation 18: 6-020-0206, 8-w, 2021.
109.
MaX, WangJ, LiJ, MaC, ChenS, LeiW, YangY, LiuS, BihlJ, and ChenC. Loading MiR-210 in endothelial progenitor cells derived exosomes boosts their beneficial effects on hypoxia/reoxygeneation-injured human endothelial cells via protecting mitochondrial function. Cell Physiol Biochem, 46: 664–675, 2018.
110.
MagentaA, GrecoS, GaetanoC, and MartelliF. Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci, 14: 17319–17346, 2013.
111.
ManicardiA, FabbriE, TedeschiT, SforzaS, BianchiN, BrognaraE, GambariR, MarchelliR, and CorradiniR. Cellular uptakes, biostabilities and anti-miR-210 activities of chiral arginine-PNAs in leukaemic K562 cells. Chembiochem, 13: 1327–1337, 2012.
112.
McCormickRI, BlickC, RagoussisJ, SchoedelJ, MoleDR, YoungAC, SelbyPJ, BanksRE, and HarrisAL. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer, 108: 1133–1142, 2013.
113.
MengZY, KangHL, DuanW, ZhengJ, LiQN, and ZhouZJ. MicroRNA-210 Promotes Accumulation of Neural Precursor Cells Around Ischemic Foci After Cerebral Ischemia by Regulating the SOCS1-STAT3-VEGF-C Pathway. J Am Heart Assoc, 7: e005052, 2018.
114.
MizunoY, TokuzawaY, NinomiyaY, YagiK, Yatsuka-KanesakiY, SudaT, FukudaT, KatagiriT, KondohY, AmemiyaT, TashiroH, and OkazakiY. miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. FEBS Lett, 583: 2263–2268, 2009.
115.
MoralesS, MonzoM, and NavarroA. Epigenetic regulation mechanisms of microRNA expression. Biomol Concepts, 8: 203–212, 2017.
116.
MovafaghS, CrookS, and VoK. Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate. J Cell Biochem, 116: 696–703, 2015.
117.
MurryCE, JenningsRB, and ReimerKA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 74: 1124–1136, 1986.
118.
MutharasanRK, NagpalV, IchikawaY, and ArdehaliH. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol, 301: H1519–H1530, 2011.
119.
NakashimaS, JinninM, KanemaruH, KajiharaI, IgataT, OkamotoS, TazakiY, HaradaM, MasuguchiS, FukushimaS, MasuzawaM, AmohY, MasuzawaM, and IhnH. The role of miR-210, E2F3 and ephrin A3 in angiosarcoma cell proliferation. Eur J Dermatol, 27: 464–471, 2017.
120.
NallamshettyS, ChanSY, and LoscalzoJ. Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med, 64: 20–30, 2013.
NiJ, ZhouS, YuanW, CenF, and YanQ. Mechanism of miR-210 involved in epithelial-mesenchymal transition of pancreatic cancer cells under hypoxia. J Recept Signal Transduct Res, 39: 399–406, 2019.
123.
NieY, HanBM, LiuXB, YangJJ, WangF, CongXF, and ChenX. Identification of MicroRNAs involved in hypoxia- and serum deprivation-induced apoptosis in mesenchymal stem cells. Int J Biol Sci, 7: 762–768, 2011.
124.
NossierAI, ShehataNI, MorsySM, SaeedDF, ElsayedNM, IsmailMF, and EissaS. Determination of certain urinary microRNAs as promising biomarkers in diabetic nephropathy patients using gold nanoparticles. Anal Biochem, 609: 113967, 2020.
125.
OsipovaJ, FischerDC, DangwalS, VolkmannI, WideraC, SchwarzK, LorenzenJM, SchreiverC, JacobyU, HeimhaltM, ThumT, and HaffnerD. Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J Clin Endocrinol Metab, 99: E1661–E1665, 2014.
126.
PerssonP and PalmF. Hypoxia-inducible factor activation in diabetic kidney disease. Curr Opin Nephrol Hypertens, 26: 345–350, 2017.
127.
PhamTP, KremerV, and BoonRA. RNA-based therapeutics in cardiovascular disease. Curr Opin Cardiol, 35: 191–198, 2020.
128.
PhuahNH, AzmiMN, AwangK, and NagoorNH. Down-regulation of MicroRNA-210 confers sensitivity towards 1'S-1'-acetoxychavicol acetate (ACA) in cervical cancer cells by targeting SMAD4. Mol Cells, 40: 291–298, 2017.
129.
PotenteM, GerhardtH, and CarmelietP. Basic and therapeutic aspects of angiogenesis. Cell, 146: 873–887, 2011.
130.
PuisségurMP, MazureNM, BerteroT, PradelliL, GrossoS, Robbe-SermesantK, MaurinT, LebrigandK, CardinaudB, HofmanV, FourreS, MagnoneV, RicciJE, PouysségurJ, GounonP, HofmanP, BarbryP, and MariB. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ, 18: 465–478, 2011.
131.
PulkkinenK, MalmT, TurunenM, KoistinahoJ, and Ylä-HerttualaS. Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett, 582: 2397–2401, 2008.
132.
QiaoA, KhechaduriA, Kannan MutharasanR, WuR, NagpalV, and ArdehaliH. MicroRNA-210 decreases heme levels by targeting ferrochelatase in cardiomyocytes. J Am Heart Assoc, 2: e000121, 2013.
133.
QinL, ChenY, NiuY, ChenW, WangQ, XiaoS, LiA, XieY, LiJ, ZhaoX, HeZ, and MoD. A deep investigation into the adipogenesis mechanism: profile of microRNAs regulating adipogenesis by modulating the canonical Wnt/beta-catenin signaling pathway. BMC Genomics 11: 320-2164-1, 1-320, 2010.
134.
QiuQ, ShenT, WangQ, YuX, JiaN, and HeQ. Cardiac shock wave therapy protects cardiomyocytes from hypoxia-induced injury by modulating miR-210. Mol Med Rep, 21: 631–640, 2020.
135.
ReichardA and AsosinghK. The role of mitochondria in angiogenesis. Mol Biol Rep, 46: 1393–1400, 2019.
136.
RenJ, LiX, DongH, SuoL, ZhangJ, ZhangL, and ZhangJ. miR-210-3p regulates the proliferation and apoptosis of non-small cell lung cancer cells by targeting SIN3A. Exp Ther Med, 18: 2565–2573, 2019.
137.
SatoY, EndoH, OkuyamaH, TakedaT, IwahashiH, ImagawaA, YamagataK, ShimomuraI, and InoueM. Cellular hypoxia of pancreatic beta-cells due to high levels of oxygen consumption for insulin secretion in vitro. J Biol Chem, 286: 12524–12532, 2011.
138.
SchödelJ, OikonomopoulosS, RagoussisJ, PughCW, RatcliffePJ, and MoleDR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood, 117: e207–e217, 2011.
139.
SemenzaGL.The genomics and genetics of oxygen homeostasis. Annu Rev Genomics Hum Genet, 21: 183–204, 2020.
140.
SemenzaGL.Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim Biophys Acta, 1813: 1263–1268, 2011.
141.
SendoelA and HengartnerMO. Apoptotic cell death under hypoxia. Physiology (Bethesda), 29: 168–176, 2014.
142.
SeokH, HamJ, JangES, and ChiSW. MicroRNA target recognition: insights from transcriptome-wide non-canonical interactions. Mol Cells, 39: 375–381, 2016.
143.
ShangC, HongY, GuoY, LiuYH, and XueYX. MiR-210 up-regulation inhibits proliferation and induces apoptosis in glioma cells by targeting SIN3A. Med Sci Monit, 20: 2571–2577, 2014.
144.
ShiYF, LiuN, LiYX, SongCL, SongXJ, ZhaoZ, and LiuB. Insulin protects H9c2 rat cardiomyoblast cells against hydrogen peroxide-induced injury through upregulation of microRNA-210. Free Radic Res, 49: 1147–1155, 2015.
145.
SongJ, YangX, and YanLJ. Role of pseudohypoxia in the pathogenesis of type 2 diabetes. Hypoxia (Auckl), 7: 33–40, 2019.
146.
Sousa FialhoMDL, Abd JamilAH, StannardGA, and HeatherLC. Hypoxia-inducible factor 1 signalling, metabolism and its therapeutic potential in cardiovascular disease. Biochim Biophys Acta Mol Basis Dis, 1865: 831–843, 2019.
147.
SunFB, LinY, LiSJ, GaoJ, HanB, and ZhangCS. MiR-210 knockdown promotes the development of pancreatic cancer via upregulating E2F3 expression. Eur Rev Med Pharmacol Sci, 22: 8640–8648, 2018.
148.
SunW, ZhaoL, SongX, ZhangJ, XingY, LiuN, YanY, LiZ, LuY, WuJ, LiL, XiaoY, TianX, LiT, GuanY, WangY, and LiuB. MicroRNA-210 modulates the cellular energy metabolism shift during H2O2-induced oxidative stress by repressing ISCU in H9c2 cardiomyocytes. Cell Physiol Biochem, 43: 383–394, 2017.
149.
TakaiY, NishimuraS, KandoriH, and WatanabeT. Histopathological significance of microRNA-210 expression in acute peripheral ischemia in a murine femoral artery ligation model. J Toxicol Pathol, 33: 211–217, 2020.
150.
TanW, LimSG, and TanTM. Up-regulation of microRNA-210 inhibits proliferation of hepatocellular carcinoma cells by targeting YES1. World J Gastroenterol, 21: 13030-13041, 2015.
151.
TangT, YangZ, ZhuQ, WuY, SunK, AlahdalM, ZhangY, XingY, ShenY, XiaT, XiT, PanY, and JinL. Up-regulation of miR-210 induced by a hypoxic microenvironment promotes breast cancer stem cells metastasis, proliferation, and self-renewal by targeting E-cadherin. FASEB J 2018. [Epub ahead of print] DOI: 10.1096/fj.201801013R.
152.
TäubelJ, HaukeW, RumpS, ViereckJ, BatkaiS, PoetzschJ, RodeL, WeigtH, GenschelC, LorchU, TheekC, LevinAA, BauersachsJ, SolomonSD, and ThumT. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J, 42: 178–188, 2021.
153.
TengX, ChenX, XueH, TangY, ZhangP, KangQ, HaoY, ChenR, ZhaoY, and HeS. NPInter v4.0: an integrated database of ncRNA interactions. Nucleic Acids Res, 48: D160–D165, 2020.
154.
ThorpEB.Mechanisms of failed apoptotic cell clearance by phagocyte subsets in cardiovascular disease. Apoptosis, 15: 1124–1136, 2010.
155.
TianF, TangP, SunZ, ZhangR, ZhuD, HeJ, LiaoJ, WanQ, and ShenJ. miR-210 in Exosomes Derived from Macrophages under High Glucose Promotes Mouse Diabetic Obesity Pathogenesis by Suppressing NDUFA4 Expression. J Diabetes Res, 2020: 6894684, 2020.
156.
TikhomirovR, DonnellBR, CatapanoF, FaggianG, GorelikJ, MartelliF, and EmanueliC. Exosomes: From Potential Culprits to New Therapeutic Promise in the Setting of Cardiac Fibrosis. Cells, 9: 592, 2020.
157.
TomaiF, CreaF, ChiarielloL, and GioffrèPA. Ischemic preconditioning in humans: models, mediators, and clinical relevance. Circulation, 100: 559–563, 1999.
158.
TongWH and RouaultTA. Functions of mitochondrial ISCU and cytosolic ISCU in mammalian iron-sulfur cluster biogenesis and iron homeostasis. Cell Metab, 3: 199–210, 2006.
159.
TsuchiyaS, FujiwaraT, SatoF, ShimadaY, TanakaE, SakaiY, ShimizuK, and TsujimotoG. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem, 286: 420–428, 2011.
160.
van den OeverIA, RatermanHG, NurmohamedMT, and SimsekS. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm, 2010: 792393, 2010.
161.
VirgaF, CappellessoF, StijlemansB, HenzeAT, TrottaR, Van AudenaerdeJ, MirchandaniAS, Sanchez-GarciaMA, VandewalleJ, OrsoF, Riera-DomingoC, GriffaA, IvanC, SmitsE, LaouiD, MartelliF, LangoucheL, Van den BergheG, FeronO, GhesquièreB, PrenenH, LibertC, WalmsleySR, CorbetC, Van GinderachterJA, IvanM, TavernaD, and MazzoneM. Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. Sci Adv, 7: eabf0466, 2021.
162.
VoellenkleC, Garcia-ManteigaJM, PedrottiS, PerfettiA, De TomaI, Da SilvaD, MaimoneB, GrecoS, FasanaroP, CreoP, ZaccagniniG, GaetanoC, and MartelliF. Implication of Long noncoding RNAs in the endothelial cell response to hypoxia revealed by RNA-sequencing. Sci Rep, 6: 24141, 2016.
163.
VoellenkleC, RooijJ, GuffantiA, BriniE, FasanaroP, IsaiaE, CroftL, DavidM, CapogrossiMC, MolesA, FelsaniA, and MartelliF. Deep-sequencing of endothelial cells exposed to hypoxia reveals the complexity of known and novel microRNAs. RNA, 18: 472–484, 2012.
164.
VreekenD, ZhangH, van ZonneveldAJ, and van GilsJM. Ephs and Ephrins in Adult Endothelial Biology. Int J Mol Sci, 21: 5623, 2020.
165.
WangF, XiongL, HuangX, ZhaoT, WuLY, LiuZH, DingX, LiuS, WuY, ZhaoY, WuK, ZhuLL, and FanM. miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells. Stem Cell Res, 11: 657–667, 2013.
166.
WangH, ZhaoY, LuoR, BianX, WangY, ShaoX, LiYX, LiuM, and WangYL. A positive feedback self-regulatory loop between miR-210 and HIF-1α mediated by CPEB2 is involved in trophoblast syncytialization: implication of trophoblast malfunction in preeclampsia†. Biol Reprod, 102: 560–570, 2020.
167.
WangL, HeJ, HuH, TuL, SunZ, LiuY, and LuoF. Lung CSC-derived exosomal miR-210-3p contributes to a pro-metastatic phenotype in lung cancer by targeting FGFRL1. J Cell Mol Med, 24: 6324–6339, 2020.
168.
WangN, ChenC, YangD, LiaoQ, LuoH, WangX, ZhouF, YangX, YangJ, ZengC, and WangWE. Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis. Biochim Biophys Acta Mol Basis Dis, 1863: 2085–2092, 2017.
169.
WangZ, DengM, LiuZ, and WuS. Hypoxia-induced miR-210 promoter demethylation enhances proliferation, autophagy and angiogenesis of schwannoma cells. Oncol Rep, 37: 3010–3018, 2017.
170.
WattsM, WilliamsG, LuJ, NithianantharajahJ, and ClaudianosC. MicroRNA-210 regulates dendritic morphology and behavioural flexibility in mice. Mol Neurobiol, 58: 1330–1344, 2021.
WilliamsonJR, ChangK, FrangosM, HasanKS, IdoY, KawamuraT, NyengaardJR, van den EndenM, KiloC, and TiltonRG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes, 42: 801–813, 1993.
173.
WinklerJ. Chapter 16: Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease. In: Epigenetics in Cardiovascular Diseases, edited by Devaux Y and Robinson EL. Trygve Tollefsbol, London, UK, 2021, pp. 349.
174.
WuJ, JinZ, ZhengH, and YanLJ. Sources and implications of NADH/NAD(+) redox imbalance in diabetes and its complications. Diabetes Metab Syndr Obes, 9: 145–153, 2016.
175.
XiaoF, QiuH, ZhouL, ShenX, YangL, and DingK. WSS25 inhibits Dicer, downregulating microRNA-210, which targets Ephrin-A3, to suppress human microvascular endothelial cell (HMEC-1) tube formation. Glycobiology, 23: 524–535, 2013.
176.
XiongL, WangF, HuangX, LiuZH, ZhaoT, WuLY, WuK, DingX, LiuS, WuY, ZhaoY, ZhuLL, and FanM. DNA demethylation regulates the expression of miR-210 in neural progenitor cells subjected to hypoxia. FEBS J, 279: 4318–4326, 2012.
177.
XuJ, HuangZ, LinL, FuM, GaoY, ShenY, ZouY, SunA, QianJ, and GeJ. miR-210 over-expression enhances mesenchymal stem cell survival in an oxidative stress environment through antioxidation and c-Met pathway activation. Sci China Life Sci, 57: 989–997, 2014.
178.
YangF, YanY, YangY, HongX, WangM, YangZ, LiuB, and YeL. MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN/PI3K/AKT pathway. Cell Signal, 73: 109675, 2020.
179.
YangQ, WangP, DuX, WangW, ZhangT, and ChenY. Direct repression of IGF2 is implicated in the anti-angiogenic function of microRNA-210 in human retinal endothelial cells. Angiogenesis, 21: 313–323, 2018.
180.
YangW, SunT, CaoJ, LiuF, TianY, and ZhuW. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res, 318: 944–954, 2012.
181.
YinC, LinX, SunY, and JiX. Dysregulation of miR-210 is involved in the development of diabetic retinopathy and serves a regulatory role in retinal vascular endothelial cell proliferation. Eur J Med Res 25: 20-020-0041, 6-3, 2020.
182.
YingQ, LiangL, GuoW, ZhaR, TianQ, HuangS, YaoJ, DingJ, BaoM, GeC, YaoM, LiJ, and HeX. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology, 54: 2064–2075, 2011.
183.
YoshiokaY, KosakaN, OchiyaT, and KatoT. Micromanaging Iron Homeostasis: hypoxia-inducible micro-RNA-210 suppresses iron homeostasis-related proteins. J Biol Chem, 287: 34110–34119, 2012.
184.
YuanHF, ChristinaVR, GuoCA, ChuYW, LiuRH, and YanZQ. Involvement of MicroRNA-210 demethylation in steroid-associated osteonecrosis of the femoral head. Sci Rep, 6: 20046, 2016.
185.
ZaccagniniG, GrecoS, LongoM, MaimoneB, VoellenkleC, FuschiP, CarraraM, CreoP, MaselliD, TironeM, MazzoneM, GaetanoC, SpinettiG, and MartelliF. Hypoxia-induced miR-210 modulates the inflammatory response and fibrosis upon acute ischemia. Cell Death Dis 12: 435-021-0371, 3-9, 2021.
186.
ZaccagniniG, MaimoneB, Di StefanoV, FasanaroP, GrecoS, PerfettiA, CapogrossiMC, GaetanoC, and MartelliF. Hypoxia-induced miR-210 modulates tissue response to acute peripheral ischemia. Antioxid Redox Signal, 21: 1177–1188, 2014.
187.
ZaccagniniG, MaimoneB, FuschiP, LongoM, Da SilvaD, CarraraM, VoellenkleC, PeraniL, EspositoA, GaetanoC, and MartelliF. Hypoxia-Induced miR-210 is necessary for vascular regeneration upon acute limb ischemia. Int J Mol Sci, 21: 129, 2019.
188.
ZaccagniniG, MaimoneB, FuschiP, MaselliD, SpinettiG, GaetanoC, and MartelliF. Overexpression of miR-210 and its significance in ischemic tissue damage. Sci Rep 7: 9563-017-0976, 3-4, 2017.
189.
ZengL, HeX, WangY, TangY, ZhengC, CaiH, LiuJ, WangY, FuY, and YangGY. MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain. Gene Ther, 21: 37–43, 2014.
190.
ZengLL, HeXS, LiuJR, ZhengCB, WangYT, and YangGY. Lentivirus-Mediated Overexpression of MicroRNA-210 Improves Long-Term Outcomes after Focal Cerebral Ischemia in Mice. CNS Neurosci Ther, 22: 961–969, 2016.
191.
ZengX, YinF, LiuX, XuJ, XuY, HuangJ, NanY, and QiuX. Upregulation of E2F transcription factor 3 is associated with poor prognosis in hepatocellular carcinoma. Oncol Rep, 31: 1139–1146, 2014.
192.
ZhangH, WuJ, WuJ, FanQ, ZhouJ, WuJ, LiuS, ZangJ, YeJ, XiaoM, TianT, and GaoJ. Exosome-mediated targeted delivery of miR-210 for angiogenic therapy after cerebral ischemia in mice. J Nanobiotechnol 17: 29-019-046, 1-7, 2019.
193.
ZhangJ, RaoG, QiuJ, HeR, and WangQ. MicroRNA-210 improves perfusion recovery following hindlimb ischemia via suppressing reactive oxygen species. Exp Ther Med, 20: 236, 2020.
194.
ZhangY, LiQ, YounJY, and CaiH. Protein Phosphotyrosine Phosphatase 1B (PTP1B) in Calpain-dependent Feedback Regulation of Vascular Endothelial Growth Factor Receptor (VEGFR2) in endothelial cells: implications in vegf-dependent angiogenesis and diabetic wound healiNG. J Biol Chem, 292: 407–416, 2017.
195.
ZhangZ, SunH, DaiH, WalshRM, ImakuraM, SchelterJ, BurchardJ, DaiX, ChangAN, DiazRL, MarszalekJR, BartzSR, CarletonM, ClearyMA, LinsleyPS, and GrandoriC. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle, 8: 2756–2768, 2009.
196.
ZhaoJ, FlorentinJ, TaiYY, TorrinoS, OhayonL, BrzoskaT, TangY, YangJ, NegiV, WoodcockCC, RisbanoMG, NouraieSM, SunddP, BerteroT, DuttaP, and ChanSY. Long range endocrine delivery of circulating miR-210 to endothelium promotes pulmonary hypertension. Circ Res, 127: 677–692, 2020.
197.
ZhaoM, WangLT, LiangGP, ZhangP, DengXJ, TangQ, ZhaiHY, ChangCC, SuYW, and LuQJ. Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol, 150: 22–30, 2014.
198.
ZhengG, TaoY, YuW, and SchwartzRJ. Brief report: SRF-dependent MiR-210 silences the sonic hedgehog signaling during cardiopoesis. Stem Cells, 31: 2279–2285, 2013.
199.
ZhengZ, LiuL, ZhanY, YuS, and KangT. Adipose-derived stem cell-derived microvesicle-released miR-210 promoted proliferation, migration and invasion of endothelial cells by regulating RUNX3. Cell Cycle, 17: 1026–1033, 2018.
